First Step for a New Immune Checkpoint Inhibitor Targeting IL4I1

Merck & Co. (MRK) has officially completed the Phase 1 trial (NCT05594043) of MK-6598, a novel immuno-oncology candidate with a unique mechanism of action. MK-6598 is a small molecule compound that selectively inhibits IL4I1 (Interleukin-4-induced gene 1), an enzyme overexpressed in immune cells and the tumor microenvironment (TME), which suppresses T-cell activity. Currently in the early stages of development with no prior approvals or reviews by regulatory bodies such as the FDA, this Phase 1 trial aimed to evaluate the safety and tolerability of MK-6598 as a single agent and in combination with pembrolizumab (Keytruda), Merck's existing immune checkpoint inhibitor, in patients with advanced solid tumors. The industry had high expectations that this new metabolic immune checkpoint inhibitor could overcome the limitations of existing immunotherapies.

Phase 1 Trial Passes Safety Test, but Combination Therapy Approaches Toxicity Threshold

In this trial, MK-6598 was evaluated at doses ranging from 50mg to 500mg, administered orally once daily. The single-agent arm demonstrated a favorable safety profile with no dose-limiting toxicities (DLTs) observed. However, the combination arm with pembrolizumab reported three DLTs, suggesting the need for careful monitoring in future combination therapy studies. This is likely due to the systemic immune activation that can occur when IL4I1, the drug's target, is inhibited, combined with the immune-enhancing effects of pembrolizumab. Although some safety concerns were raised, the fact that a suitable dosage range was identified for the majority of patients with solid tumors is a positive development.

Limited Anti-Cancer Efficacy Falls Short of Expectations

Despite expectations from the academic and investment communities, preliminary efficacy data presented at AACR 2025 indicated that the tumor-inhibiting effect of MK-6598 was lower than expected. Across both the single-agent and combination therapy arms, most patients did not exhibit significant clinical benefit, and overall efficacy remained limited. Notably, one patient with mismatch repair deficient (dMMR) endometrial cancer, who had previously failed Keytruda treatment, showed a partial response (PR), strongly suggesting the need for future patient selection based on specific biomarkers. This highlights the scientific lesson that inhibiting IL4I1 alone may not be sufficient to completely control the complex immune evasion mechanisms of tumors.

Strategic Implications for Overcoming Immunotherapy Resistance in the Market

Currently, the global cancer immunotherapy market is estimated at approximately $136 billion, and numerous global pharmaceutical companies are competing to overcome the resistance to PD-1 inhibitors such as Keytruda. As with the past clinical failure of epacadostat, an IDO1 inhibitor, the development of therapies that regulate tumor amino acid metabolism has faced numerous challenges. Merck's Phase 1 results also reaffirm that, rather than as a single-agent therapy, this compound needs to be redesigned for combination therapy and targeted to a narrower patient population to overcome the immune-suppressive microenvironment. In the future, Merck is likely to adjust the development speed of this compound or revise its pipeline strategy by focusing on specific patient populations such as dMMR.